Seeking Alpha2d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Business Wire1mon
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
ETF Daily News3d
Vertex Pharmaceuticals (VRTX) to Release Earnings on Monday
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
clinicaladvisor.com28d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional ... 6 years and older with at least 1 qualifying non-F508del Trikafta-responsive mutation and with no exclusionary mutation.
Vertex stock price target cut to $533 by Piper Sandler
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...
Benzinga.com15d
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options ... If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as ...
MarketWatch1mon
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
Vertex Pharmaceuticals said Friday the U.S. Food ... The medicine, called trikafta, can treat cystic fibrosis patients who have at least one F508del mutation in the transmembrane conductance ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Business Insider1mon
Vertex Pharmaceuticals price target lowered to $500 from $503 at JPMorgan
JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX ... Alyftrek’s approval with a higher U.S. price than Trikafta sets the stage for continued Cystic Fibrosis revenue ...
Yahoo Finance13d
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts
Vertex Pharmaceuticals is a global biotechnology ... Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care ...
Yahoo Finance1mon
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...